Application Nr Approved Date Route Status External Links
ANDA208531 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Ticagrelor Tablets Are Indicated To Reduce The Rate Of Cardiovascular Death, Myocardial Infarction, And Stroke In Patients With Acute Coronary Syndrome (Acs) Or A History Of Myocardial Infarction (Mi). For At Least The First 12 Months Following Acs, It Is Superior To Clopidogrel. Ticagrelor Tablets Also Reduce The Rate Of Stent Thrombosis In Patients Who Have Been Stented For Treatment Of Acs [See Clinical Studies (14.1) ] . Ticagrelor Tablets Are A P2y 12 Platelet Inhibitor Indicated To Reduce The Rate Of Cardiovascular Death, Myocardial Infarction, And Stroke In Patients With Acute Coronary Syndrome (Acs) Or A History Of Myocardial Infarction (Mi). For At Least The First 12 Months Following Acs, It Is Superior To Clopidogrel. Ticagrelor Tablets Also Reduce The Rate Of Stent Thrombosis In Patients Who Have Been Stented For Treatment Of Acs. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Ticagrelor TICAGRELOR ZINC28957444

Comments